City

Basking Ridge (2)

Commack (2)

Harrison (2)

Middletown (2)

Montvale (2)

New York (2)

Uniondale (2)

Condition

Fumarate Hydratase Deficient Renal Cell Carcinoma (3)

Succinate Dehydrogenase Deficient Renal Cell Carcinoma (2)

Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (1)

Chromophobe Renal Cell Carcinoma (1)

Collecting Duct Renal Cell Carcinoma (1)

Metastatic Renal Cell Carcinoma (1)

Papillary Renal Cell Carcinoma (1)

Unclassified Renal Cell Carcinoma (1)

Overall Status

Recruiting (2)

Not yet recruiting (1)

Sign in for free

Phase

phase 2 (3)

Sponsor

Memorial Sloan Kettering Cancer Center (2)

RenJi Hospital (1)

Collaborator

Intervention

avelumab (1)

cabozantinib (1)

lenvatinib (1)

nivolumab (1)

talazoparib (1)

tislelizumab (1)

Study Documents

Intervention Type

drug (3)

biological (1)

Funder Type

Other (3)

Study Type

Interventional (3)

fumarate hydratase deficient renal cell carcinoma

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Fumarate Hydratase Deficient Renal Cell Carcinoma Trial (Tislelizumab, Lenvatinib)

Not yet recruiting

Fumarate Hydratase Deficient Renal Cell Carcinoma

Tislelizumab
Lenvatinib

(no location specified)

May 18, 2023

Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Papillary Renal Cell Carcinoma

Recruiting

Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma
+6 more

Basking Ridge, New Jersey
+6 more

Feb 2, 2022

Metastatic Renal Cell Carcinoma, Fumarate Hydratase Deficient Renal Cell Carcinoma, Succinate Dehydrogenase Deficient Renal Cell

Recruiting

Metastatic Renal Cell Carcinoma
+2 more

Basking Ridge, New Jersey
+6 more

Dec 21, 2021